Are Buscopan (Hyoscine) patches safe in patients with Cardiovascular Disease (CVD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the FDA Drug Label

PRECAUTIONS General:Use with caution in patients with: ... coronary heart disease, congestive heart failure, cardiac arrythmias, hypertension, and renal disease. The hyoscine (TD) patch, also known as buscopan, should be used with caution in patients with cardiovascular disease (CVD), including coronary heart disease, congestive heart failure, cardiac arrhythmias, and hypertension 1.

  • The drug label advises to investigate any tachycardia before giving any anticholinergic drug since they may increase the heart rate.
  • It is recommended to use caution when administering the drug to patients with these conditions.

From the Research

Buscopan patches are not a standard formulation of the medication, and their safety in patients with cardiovascular disease (CVD) is not established, therefore, alternative antispasmodics with fewer cardiovascular effects, such as mebeverine, might be more appropriate for CVD patients. For patients with CVD, standard Buscopan should be used with caution, as it can potentially cause tachycardia and other anticholinergic effects that may exacerbate certain cardiovascular conditions 2. The anticholinergic properties of Buscopan work by blocking muscarinic receptors, reducing smooth muscle spasms in the gastrointestinal tract, but these same effects can impact heart rate and rhythm.

Key Considerations

  • Patients with pre-existing heart conditions such as coronary heart disease, cardiac arrhythmias, or heart failure should consult their healthcare provider before using Buscopan.
  • The typical oral dose is 10-20 mg taken up to four times daily, but this may need adjustment in CVD patients.
  • Mebeverine has been shown to be an effective treatment option in irritable bowel syndrome (IBS) with a good safety profile and low frequency of adverse effects 3.
  • Always inform your healthcare provider about all your medical conditions and medications before starting Buscopan.

Alternative Treatment Options

  • Mebeverine might be a suitable alternative for CVD patients, given its efficacy and safety profile in treating abdominal pain and IBS symptoms 3.
  • Other antispasmodics, such as alverine, dicyclomine, hyoscine, hyoscyamine, otilonium, pinaverium, and trimebutine, may also be considered, but their efficacy and safety in CVD patients should be evaluated on an individual basis 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.